secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dyne Therapeutics, Inc. (DYN)
CIK:        0001818794
Form:       8-K
Filed at:   2025-12-10T23:59:59+00:00
Accession:  0001193125-25-314249
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyne Therapeutics prices upsized $350M public offering at $18.44/share
----------------------------------------------------------------------

- Priced 18,980,478 shares at $18.44/share; gross proceeds $350M.
- Underwriters granted 30-day option for additional 2,847,071 shares.
- Net proceeds estimated at ~$328.5M ($377.9M if option exercised).
- Also borrowed $50M second tranche under Hercules Loan Agreement.
- Cash runway extended into Q1 2028 with combined resources.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818794/000119312525314249/0001193125-25-314249-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818794/000119312525314249/d76666d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-314249

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer